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Abstract: A growing body of evidence indicates that matrix metalloproteinases (MMPs) play 
a role in the pathogenesis of COPD. Therefore, we conducted a candidate gene association 
study of 4 promoter polymorphisms that are known to modify expression levels of the 
MMP-1, MMP-2, and MMP-9 genes and a Gln279Arg polymorphism in exon 6 of MMP-9 
that modiﬁ  es the substrate-binding region. We examined the association of each variant and 
haplotypes in 385 male veterans with greater than 20 pack-years of cigarette smoking whose 
COPD status was characterized using spirometry. The association of these polymorphisms 
was also examined with decline of pulmonary function in a subset of participants. Only the 
279Arg variant was more common in participants with COPD and the homozygous variant 
was associated with a 3-fold increased risk for COPD. In the haplotype analysis, the haplotype 
comprising the 249Arg and the CA promoter polymorphism within the MMP-9 gene was 
associated with risk, suggesting that either 279Arg or a linked variant on this haplotype 
underlies the association. No association of this polymorphism was found with decline in 
pulmonary function. These studies show that variants of the MMP-9 gene are associated with 
COPD in this cohort of veterans.
Keywords: metalloproteinase, smoking, pulmonary function, single nucleotide polymorphism, 
molecular epidemiology
Introduction
Genetic factors likely play a critical role in the development of COPD, because only 
a minority of heavy smokers develops this disease. The ﬁ  rst genetic defect associated 
with COPD was a deﬁ  ciency in α1-antitrypsin (Ganrot et al 1967). However, other 
genetic variations that affect the proteinase–antiproteinase imbalance (Evans and 
Pryor 1994) also likely affect the onset and development of COPD, because only 
<1% of COPD cases are associated with α1-antitrypsin deﬁ  ciency (Sandford 
et al 2002).
A role for the matrix metalloproteinases (MMPs) has been suggested in the 
pathogenesis of pulmonary emphysema (Barnes 2000). Immunoreactivity for 
MMP-1, MMP-2, and MMP-9 is more intense in emphysematous samples compared 
with normal lung tissue (Ohnishi et al 1998; Segura-Valdez et al 2000). Alveolar 
macrophages obtained from smokers release more MMP-9 than those from non-
smokers (Lim et al 2000). 
There is an insertion–deletion polymorphism in the promoter region of the 
MMP-1 gene (1G-1607/2G). The addition of G in the MMP-1 promoter creates an 
Ets binding site, and leads to higher transcription of the protein compared with the 
common 1G polymorphism (Rutter et al 1998). The incidence of the 2G allele rises 
to 62% in tumor cells in ovarian and endometrial carcinomas (Rutter et al 1998). A 
single nucleotide polymorphism (SNP) in the MMP-2 promoter sequence (-1306 
C→T) disrupts a SP1 site and results in lower promoter activity with the T allele 
(Price et al 2001), and participants homozygous for C have an overall 2-fold increased 
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risk for developing lung cancer compared with those with the 
CT or TT genotype (Yu et al 2002). We chose to study the 
association of these SNPs with COPD, because participants 
with COPD are at higher risk of developing lung cancer 
(Cohen et al 1977; Wu et al 1995).
Sequence analysis of the MMP-9 gene revealed a total 
of 10 variable sites, 4 in the promoter, 5 in the coding 
region (3 of which alter the amino acid encoded), and 
1 in the 3′ untranslated region (Zhang et al 1999a). The 
variable length CA repeat located at –90 bp within the 
promoter region of MMP-9 may affect promoter activity 
and creates a sequence-speciﬁ  c DNA-binding protein site 
(Peters et al 1999). A C→T polymorphism at –1562 bp 
results in higher transcription rates for the T allele than the 
C allele promoter (Zhang et al 1999b) and dysregulation of 
MMP-9 function could increase susceptibility for smoking-
induced airway obstruction. A polymorphism in exon 6 
of MMP-9 is located in the substrate-binding domain of 
this enzyme and leads to a substitution of an uncharged 
amino acid (glutamine) by a positively charged amino 
acid (arginine). This polymorphism likely alters protein 
conformation, leading to a change in substrate-binding 
and enzyme activity, while the other two polymorphisms 
in the coding region that lead to altered amino acids are not 
likely to have such a profound change in enzyme activity 
(Zhang et al 1999a). 
The major ethnic groups in New Mexico, the area from 
which the study population was recruited, consist of non-
hispanic whites and hispanics. Therefore, the present study 
analyzed the prevalence of COPD in these ethnic groups 
and determined whether potentially functional variants that 
include the promoter regions of MMP-1, MMP -2, and MMP 
-9 and the Glu279Arg polymorphism within MMP-9 gene are 
associated with COPD in a cross-sectional study of veteran 
men and within the major ethnic groups.
Material and methods
Study population
Study participants were drawn from an ongoing cohort 
study of veterans (n=385). Participants were recruited from 
the New Mexico Veterans’ Health Care System, which 
provides medical care for approximately 35 000 veterans in 
New Mexico, west Texas, and southern Colorado. Inclusion 
criteria included age 40–75 years and a minimum smoking 
history of ≥20 pack-years. Informed consent was obtained 
from each participant prior to completing a standardized 
clinical examination including spirometry and a standardized 
questionnaire that provided detailed information on 
demographics, smoking history, and respiratory health. 
Phlegm production was assessed by evaluating the St. 
George’s Respiratory Disease Questionnaire. The same 
information was obtained at a follow-up visit at 18±3 
months for 176 participants. This study was approved by 
the Institutional Review Boards of the Lovelace Respiratory 
Research Institute, the New Mexico Veterans Health Care 
System, and the University of New Mexico Health Sciences 
Center. 
COPD deﬁ  nition
COPD was deﬁ  ned by criteria similar to those suggested 
as part of the GOLD criteria (Pauwels et al 2001) and 
were used in the Lung Health Study (Anthonisen et al 
1994) and recently described by the ATS/ERS Task Force 
(Celli and MacNee 2004). We did not break down the 
cohort into various GOLD categories, because of small 
cell size for GOLD 1-4. However, three deﬁ  nitions for 
COPD were used: Deﬁ  nition I included all participants with 
FEV1/FVC<70% as measured by spirometry. Deﬁ  nition 
II included only participants with FEV1/FVC<70% and 
who had FEV1<80% as cases and all other participants 
who were deﬁ  ned as COPD participants in Deﬁ  nition I 
were excluded from the analyses. Deﬁ  nition III included 
only participants with FEV1/FVC<70% and FEV1<80%, 
excluding all who had reversibility of >15% post-
bronchodialator exposure. Reversibility was deﬁ  ned as the 
percent change in percent predicted FEV1 between pre- and 
post-bronchodialator exposures. For all three deﬁ  nitions, 
participants were considered to be non-COPD if FEV1/
FVC≥70%. Participants who met the criteria for diagnosis 
of COPD at cohort entry were classiﬁ  ed as prevalent cases. 
Participants with mild COPD were excluded in Deﬁ  nition 
II to reduce the potential for including participants who 
have “borderline” airﬂ  ow obstruction and participants 
who have reversible airﬂ  ow obstruction were excluded in 
Deﬁ  nition III to exclude the majority of participants who 
have asthma. 
Genotyping of polymorphisms in MMP-9 
Genomic DNA was isolated from peripheral blood 
lymphocytes by digestion with proteinase K in sodium 
dodecyl sulfate (1%), followed by standard phenol–
chloroform extraction and ethanol precipitation as 
described (Sambrook et al 1989). The sequence ﬂ  anking 
the polymorphic region of each SNP was ampliﬁ  ed by 
PCR using 10 ng of DNA. Negative controls without DNA 
template were included with each set of reactions. Several International Journal of COPD 2006:1(3) 269
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methods of genotyping were used to verify the obtained 
results. Restriction fragment length polymorphism (RFLP) 
was performed on 50–100 samples to verify the results 
obtained by the allelic discrimination assay. This assay 
integrates PCR and detection using allelic discrimination, 
which applies allele-speciﬁ  c TaqMan probes, a two-dye 
reporter system, and a reference dye. Wild-type and variant 
reporter sequences were discriminated using dual labeled 
reporters and by using mismatched sequences to validate 
the SNP-genotype. To further ensure quality control, DNA 
samples from 20 participants whose allelotypes were known 
were included at random within each of the 96-well plates of 
the allelic discrimination assay. In addition, approximately 
10% of the samples were re-examined by a different 
person. All analyses were performed blinded with respect 
to participants’ characteristics. These controls showed 100% 
concordance with expected results.
The methods of genotyping, including the primers and 
probes for allelic discrimination of SNPs in MMP-1, MMP-2, 
and MMP-9 or enzyme used for RFLP, are listed in Table 1. 
The C→T polymorphism was analyzed using a RFLP assay, 
because several attempts to design primers and probes for 
this polymorphism failed. The presence of the rare T allele 
introduces a restriction site for SphI, which is absent when 
the common C allele is present.
The number of CA repeats in the promoter region of 
MMP-9 was determined by PCR using a fluorescently 
labeled 6-FAM forward primer and an unlabeled reverse 
primer. The alleles were separated by a laser-based 
automated DNA sequencer, ABI PRISM 3100. The product 
peaks were visualized using GenescanView software (Bio 
Molecular Research, Padova, Italy). The size of the PCR 
products was calculated from a standard curve made from 
internal standards. DNA standards containing 14, 21, 22, 
and 23 CA repeats were identiﬁ  ed by direct sequencing and 
were included in each experiment as positive controls. For 
unknown reasons, the polymorphisms of certain samples 
(1%–5%) could not be assessed even upon repeated attempts, 
resulting in slight sample size variability for the various 
polymorphisms. 
Statistical analysis 
We examined summary information by COPD status for 
demographic variables (age, gender, ethnicity); clinical risk 
factors (current smoking status, duration and pack-years of 
cigarette smoking); and polymorphism status (homozygous-
rare, heterozygous, homozygous-common). The chi-
square test and Fisher’s exact test were used to compare 
categorical variables, including gene polymorphisms 
between participants with and without COPD. Continuous 
variables such as age and smoking duration were compared 
using either the two-sample t-test or the Wilcoxon rank sum 
test. The small number of women (17 in total) enrolled in 
the larger cohort were excluded from the analysis cohort of 
385 veteran men, but this exclusion and inclusion of these 
women did not change any of the conclusions. 
Distributions of genotypes were assessed for Hardy-
Weinberg equilibrium using a generalization of Fisher’s 
exact test (Guo and Thompson 1992). All pairs of 
MMP-9 loci (T-1562, 279Arg, and CA repeats) were 
tested for linkage disequilibrium using likelihood tests 
and permutation procedures to estimate significance 
levels (Goudet et al 1996; Slatkin and Excofﬁ  er 1996) as 
implemented in PowerMarker v3.12 (Liu and Muse). The 
degree of disequilibrium was described using D′ (Lewontin 
1964; Zapata et al 2001).
Logistic regression models were ﬁ  t to estimate odds 
ratios (OR) for COPD and to allow adjustment for multiple 
covariates. We estimated effects for dominant, co-dominant, 
and recessive models for the variant alleles. Covariates in 
Table 1 PCR primers and probes for detecting polymorphisms
Polymorphism   Primers   Probes 
MMP-1 G/GG-1607   5 ′-GTTATGCCACTTAGATGAGGAAATTG (S)   5 ′-AGATAAGTCATATCCTTTCT 
   5 ′-CATAAACAATACTTCAGTATATCTTGGATTGA (AS)   5 ′-AGTCATATCTTTCTAATTAT 
MMP-2 C/T -1306   5 ′-CCCTAAAACATTCCCCATA TTCC (S)   5 ′-CACTCCACCTCTTTA 
   5 ′-GTGACTTCTGAGC TGAGACCTGAA (AS)   5 ′-AGCACTCTACCTCTT 
MMP-9 C/T -1562   5 ′-GCCTGGCACATAGTAGGCCC (S)    No SphI site (C) 
   5 ′-CTTCCTAGCCAGCCGGCATC (AS)    SphI site 300+260 bp (T) 
MMP-9 Gln279Arg   5 ′-TCTCCCCCTTTCCCACATC (S)   5 ′-CTCTACACCCGGGACGGCAATG 
   5 ′-TGTGCTGTCTCCGCCTTCT (AS)   5 ′-ACTCTACACCCAGGACGGCAATGC 
MMP-9 CA repeat   5 ′-6FAM-AAGCCCTTTCTCATGCTGGTGC   Fragment  analysis 
   5 ′-TGACAGGCAAGTGCTGACTCAG    
NOTE:  The bold, underlined letters are the single nucleotide polymorphisms designed in the probes for allelic discrimination.
Abbreviations: AS, antisense primer; S, sense primer.International Journal of COPD 2006:1(3) 270
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all models included age, ethnicity, and smoking information 
(former or current, or the continuous forms of smoking 
duration and pack-years). Logistic regression models for 
each polymorphism were ﬁ  tted and the indicators were 
included as predictors for only those polymorphisms at 
one region plus the covariates. Since there was linkage 
disequilibrium between some of the polymorphisms, the 
polymorphisms were examined separately. Interactions 
between the genotypes and each covariate, especially 
cigarette smoking (duration and pack-years), and 
interactions between the covariates also were investigated. 
To assess differences by ethnicity, models were ﬁ  tted 
separately by ethnic group. Likelihood ratio tests were 
used to test models and Wald’s chi-square tests were used 
to evaluate whether individual variables contributed to the 
model. Linear regression models were used to assess the 
association between the genetic predictor variables and the 
predicted FEV1. Covariates and interactions were included 
in the modeling as done for the logistic regression models 
above. All standard statistical testing and modeling were 
conducted using Statistical Analysis System SAS v8.02. 
(SAS Institute, Inc., Cary, NC, USA). These analyses were 
done for each of the COPD deﬁ  nitions. Therefore, the 
analyses ranged from mild to moderate and severe cases 
as the outcome. 
The association between estimated haplotype frequencies 
and COPD was evaluated with a two-stage process. First, 
MMP-9 haplotype frequencies based on T-1562, 279Arg, 
and CA repeats were estimated using Excoffier and 
Slatkin’s maximum likelihood algorithm (Excofﬁ  er and 
Slatkin 1995). For each possible haplotype, h, an estimate 
is made of the number of copies of h contained in the true 
pair of haplotypes carried by that individual conditional 
on the observed genotype and assuming Hardy-Weinberg 
equilibrium. The expected haplotype frequencies are 
analogous to haplotype dosages and were used in the second 
step as independent variables in logistic regression models 
that also included adjustment for age, smoking duration, 
and smoking status. Haplotype dosages for each participant 
were calculated separately for non-hispanic whites and 
hispanics. For other and unknown ethnicity, haplotype 
doses were calculated based on the overall cohort. Second, 
logistic regression analyses were conducted as outlined 
previously. 
Results
Description of study population 
The demographics of the cohort are summarized by COPD 
status as per deﬁ  nition I, which includes mild to severe 
cases (Table 2). The prevalence of COPD was 32% and, as 
Table 2 Summary of demographic and baseline variables plus information on baseline PFT for all participants and those with two 
visits
   All  participants      Participants with 2 visits 
   COPD
a    Non-COPD   COPD
a    Non-COPD 
N (%)   123(31.9)   262(68.1)   48  (27.3)   128  (72.7) 
Age class (years) N (%)             
40–49   6  (4.9)   42  (16.0)   4  (8.3)   15  (11.7) 
50–59   30  (24.4)   112  (42.7)   11  (22.9)   54  (42.2) 
60–69   56  (45.5)   74  (28.2)   19  (40.0)   41  (32.0) 
>=70   31  (25.2)   34  (13.0)   14  (29.2)   18  (14.1) 
Ethnicity N (%)             
Non-hispanic white   90  (73.2)   162  (61.8)   38  (79.2)   83  (64.8) 
Hispanic   20  (16.3)   61  (23.3)   5  (10.4)   28  (21.9) 
Other   13  (10.6)   39  (14.9)   5  (10.4)   17  (13.3) 
              
Current smoker yes/no   54/69   109/153   20/28   42/86 
(%)   (43.9)   (41.6)   (41.7)   (32.8) 
Smoking             
Duration (years)   40.4   33.7   40.2   33.0 
average (min, max)   (5.0–60.0)   (10.0–60.0)   (6.0–60.0)   (10.0–60.0) 
Smoking, pack-years   60.1   49.1   60.0   51.6 
average (min, max)   (20.0–220.0)   (20.0–140.0)   (24.0–205.0)   (20.0–140.0) 
  Baseline %FEV1 (average (min, max))   58.6  (19.0–99.0)   84.1  (40.0–120.0)   61.5  (33.0–87.0)   84.6  (57.0–113.0) 
aUsing COPD deﬁ  nition I.International Journal of COPD 2006:1(3) 271
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expected for a disease that increases in frequency with age, 
overall the age of participants with COPD was older than 
for non-COPD participants. The median age for participants 
with and without COPD was 64 and 57 years (p<0.001), 
respectively. Interestingly, a higher proportion of non-
hispanic white participants (36%) had COPD than hispanic 
participants (25%) (p=0.07). The number of participants 
included in analyses for COPD definitions II and III 
decreased to 366 and 339, respectively.
Average smoking duration and pack-years were greater 
for participants with COPD than for participants without 
COPD (p<0.001). Furthermore, the unadjusted OR for COPD 
was 2.1 and 2.0 for every 10 additional years of smoking 
duration and age, respectively (p<0.001). Finally, COPD 
was signiﬁ  cantly associated with phlegm production when 
adjusted for age and smoking duration (OR=2.0, 95% CI=1.4 
to 3.0; p<0.001). These basic demographic and clinical risk 
factors are similar to those reported in other studies of COPD 
(Zayas et al 1990) and reinforce the utility of our cohort for 
evaluating the role of polymorphisms within the MMP-9 
gene as risk modiﬁ  ers for COPD.
In general the percentages for COPD participants, 
ethnic distribution, smoking duration, and pack-years, and 
the baseline %FEV1 for the participants with a second visit 
remained identical to those for the overall cohort who came 
for the ﬁ  rst visit (Table 2). Repeat testing was performed on 
these participants with 90% concordance of those initially 
classified with chronic airflow obstruction. These tests 
established the chronicity of airﬂ  ow limitation through 
demonstration of FEV1/FVC<70% by spirometry that was 
not reversed into the normal range after a bronchodilation, 
but had an overall tendency of decline over time (Pauwels 
et al 2001). No mean linear change in pulmonary function 
test was found in non-COPD participants within the 
participants with repeat measurements. However, there was 
a signiﬁ  cant difference in yearly decline of %FEV1 for the 
COPD participants (2.6 (95% CI: 1.4–3.8)) compared with 
that of non-COPD participants (0.81 (95% CI: –0.01 to 
1.62)) (p<0.02).
Distribution of genotypes 
The SNPs were determined in DNA samples from 385 study 
participants. CA repeats of 14, 21, 22, and 23 were most 
frequently found while the frequency of other repeat lengths 
was below 2% (Figure 1). The CA repeat lengths that were 
most frequently found as genotypes were 14/14 (27%), 14/21 
(20%), 14/22 (16%), 14/23 (8%), 21/21 (11%), and 22/22 
(5%). The frequency of all other alleles was below 2% (Table 
3). Because the frequency distribution of the CA repeat 
polymorphism showed a bimodal distribution of alleles, the 
alleles were divided into two subclasses: CA repeats ≤16 and 
≥17 were designated as Short and Long, respectively, and 
treated similarly to genotype data.
The distributions of homozygotes and heterozygotes 
for each polymorphism in each ethnic group generally 
conformed to expectations under the assumption of Hardy-
Weinberg equilibrium, with the exception of the CA-repeat 
among hispanic participants (p=0.02). As a measure for 
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linkage disequilibrium, D′ was determined. The 279Arg 
was in linkage disequilibrium with both T-1562 (p<0.001) 
and CA repeat (p<0.001) within the ethnic groups. Of 
particular note, all participants with the homozygote 
rare T-1562 (N=20) had rare 279Arg. However, many 
participants who were homozygous for 279Arg had 
the C-1562 (Table 4). No differences among cases and 
controls were observed for any of the genotypes in MMP-1 
and MMP-2.
A difference in prevalence of the 279Gln (35.0 vs 52.1, 
p<0.01) and 279Arg (18.7% vs 7.7%, p<0.01) homozygote 
genotypes was seen in participants with COPD compared 
with non-COPD participants (Table 4) and among the 
COPD and non-COPD participants at the second visit (see 
Appendix Table 4). Signiﬁ  cantly different distributions of 
the homozygote rare 279Arg were also observed within 
the non-hispanic white participants (p<0.01). This trend in 
difference was recapitulated within the hispanic participants, 
but was not signiﬁ  cant due to the lower number of hispanic 
participants with COPD. The rare T-1562 allele, the CA 
repeat lengths, and the SNPs in MMP-1 and MMP -2 were 
distributed similarly among the participants with and without 
COPD in the veterans’ cohort (Table 4). The results for 
COPD deﬁ  nitions II and III remained identical, in that the 
distribution for the Gln279 was 52% compared with 7.7% 
for the Arg279. For both COPD deﬁ  nitions II and III, 
the distribution for Gln279 remained at 47% in non-
hispanic white participants compared with 9% for the rare 
Arg279. 
Association of allelotype with COPD 
The rare 279Arg variant was signiﬁ  cantly associated with 
COPD (Table 5). This table gives the odds ratios which is 
the odds for COPD relative to the odds for those without 
COPD. After adjustment for age, smoking duration, and 
current smoking status, the OR for COPD participants 
who were homozygous for 279Arg variant was 3.8 relative 
to those who were homozygous for the common allele 
(p<0.01). In addition, participants who were heterozygous 
also showed a signiﬁ  cant increased risk for the disease 
(OR=1.8; p<0.05), indicating a co-dominant association 
between 279Arg and COPD. This association was signiﬁ  cant 
within the non-hispanic white but not within the hispanic 
participants, likely because of limited sample size for this 
ethnic group. Among the non-hispanic white participants, 
signiﬁ  cant associations between COPD and the homozygous 
rare T-1562 (OR=4.5; p<0.05) and the Long/Long form 
of CA repeat (OR=2.3, p<0.05) were observed. Similar 
results were obtained for COPD deﬁ  nitions II and III (see 
Appendix Table 5). For example, for COPD deﬁ  nition II for 
the Gln279Arg the OR for the homozygote rare genotype 
remained signiﬁ  cant at 3.13 (95% CI: 1.4–6.9) and in non-
hispanic white participants at 2.8 (95% CI: 1.1–6.8). For 
COPD deﬁ  nition III, the OR was 3.1 (95% CI: 1.4–7.3) and 
3.3 (95% CI: 1.3–8.4) overall and for non-hispanic whites, 
respectively. No association with COPD was found for the 
variants in MMP-1 and MMP -2. The similarity of results 
between the ethnic groups and among the deﬁ  nitions of 
COPD indicates that multiple comparison adjustments 
are not needed for these factors. All models showed that 
smoking variables, including duration, pack-years, and 
current status, were signiﬁ  cantly associated with COPD, 
but none of the variables was a co-founder with the genetic 
variables. 
Gene–gene and gene–environment interaction effects 
were evaluated by adding interaction terms in logistic 
regression models that included adjustments for age and 
smoking duration. To assess differences by ethnicity, analyses 
were done separately for non-hispanic white and hispanic 
participants. The gene–environment interactions used 
cigarette smoking measures as the environmental factors. 
We found no signiﬁ  cant gene–gene or gene–environment 
interaction effects.
Table 3 Distribution of CA repeat alleles 
Allele 1   Allele  2   Frequency   Percent 
14   14   97   26.5 
18   14   1   0.3 
19   14   4   1.1 
20   14   2   0.5 
21   14   74   20.2 
21   15   2   0.5 
21   19   1   0.3 
21   21   39   10.8 
22   14   57   15.6 
22   15   3   0.8 
22   19   2   0.5 
22   20   1   0.3 
22   21   7   1.9 
22   22   17   4.6 
23   14   28   7.6 
23   15   1   0.3 
23   19   1   0.3 
23   21   9   2.6 
23   22   2   0.5 
23   23   6   1.6 
24   14   6   1.6 
24   21   3   0.8 
25   14   1   0.3 
26   21   2   0.5 International Journal of COPD 2006:1(3) 273
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Association of SNPs with the decline 
in pulmonary function–longitudinal 
analyses
While we did not see a decline in pulmonary function 
over time when analyzing the data of the entire 
population, non-hispanic white participants and those who 
smoked more than 40 pack-years showed a statistically 
signiﬁ  cant decrease per year when the raw or percentage 
difference of the baseline value in FEV1 was analyzed. 
Non-hispanic whites showed an average decrease of 1.2 
(95% CI: 0.5–1.9) or 1.7% (95% CI: 0.7–2.6), respectively, 
per year. Those who smoked ≥40 pack-years showed 
an average decrease of 1.6 (95% CI: 0.6–2.7) or 2.1% 
(95% CI: 0.8– 3.4%), respectively per year. However, 
we did not see any association of the polymorphisms 
tested with decline in pulmonary function assessed over 
18 months, while the distribution of polymorphisms 
by COPD status was identical to that observed for all 
participants.
Haplotype analyses
Haplotype (common [C], rare [R], long [L], short [S]) 
frequencies formed from MMP-9 C/T-1562, MMP-9 
Gln279Arg, and CA repeats were estimated for each cohort 
and ethnic group and evaluated for differences with respect 
to COPD status (Table 6). ORs adjusted for age, smoking 
duration, and current smoking status were calculated relative 
to the common C-1562, Gln279, and short CA repeats (C-
C-S) for haplotypes with frequencies >0.005 (Table 6). The 
haplotypes with signiﬁ  cant association with COPD were C-
R-L (1.8, 95% CI, 1.1–2.9) and R-R-L (1.7, 95% CI, 1.1–2.7) 
compared with the C-C-S haplotype. Participants with the 
haplotype including the T-1562 and the rare 279Arg showed 
the same OR as participants with the haplotype, including 
the C-1562 and the rare 279Arg, indicating that either the 
279Arg polymorphism is the main determinant or another 
variant on this RL haplotype may underlie the increased 
association by MMP-9 and risk for COPD. Models with 
and without covariates were compared using likelihood 
ratio tests. Models with haplotype dosages were no better 
Table 4 Distribution of genotypes in COPD and non-COPD participants (%)
     All   Non-hispanic  white     Hispanic 
       Non-    Non-    Non-
   COPD   COPD   COPD   COPD   COPD   COPD 
MMP-9
a   Gln279Arg   C   35.0     52.1
**    34.4   47.8
*    40.0   67.2
* 
   H   46.3   40.2   43.3   42.9   55.0   31.2 
   R   18.7     7.7 
**    22.2   9.3
**    5.0   1.6 
   n   123   261   90   161   20   61 
                      
MMP-9
a  C/T-1562   C   68.9   75.9   65.1   73.7   80.0   87.9 
   H   26.0   21.7   27.9   23.7   20.0   12.1 
   R   5.0   2.4   7.0   2.6   0.0   0.0 
   n   119   253   86   156   20   58 
                      
MMP-9
b  CA repeat   SS   24.2   27.6   29.9   36.2   5.0   13.6 
   LS   46.7   50.0   42.5   49.0   65.0   54.2 
   LL   29.2   22.4   27.6   14.8
*    30.0   32.2 
   n   120   246   87   149   20   59 
                      
MMP-1
a   C   26.2   27.2   23.6   19.8   45.0   42.6 
   H   46.7   46.3   41.6   49.0   55.0   42.6 
   R   27.1   26.5   34.8   31.2   0.0   14.8 
   n   122   257   89   157   20   61 
                      
aMMP-2   C   62.3   55.0   62.9   53.2   60.0   57.4 
   H   32.0   38.0   32.6   40.5   30.0   36.1 
   R   5.7   7.0   4.5   6.3   10.0   6.6 
   n   122   258   89   158   20   61 
aFor MMP-9 Gln279Arg, C-1562T, MMP-1, and MMP-2: C=common, H=heterozygote, R=rare.
bFor MMP-9 CA repeat length: S=Short, L=Long.
Difference between COPD (by deﬁ  nition I) and non-COPD participants: ** p<0.01, *p<0.05.International Journal of COPD 2006:1(3) 274
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than covariate-only models for predicting COPD status of 
hispanic veterans. Haplotype information was useful for 
predicting COPD in non-hispanic white veterans; however, 
the only adjusted OR different from the reference haplotype, 
C-C-S, was R-R-L (p=0.02, OR=2.0, 95% CI=1.1–3.4).
Discussion 
This cross-sectional study provides evidence that the tested 
polymorphisms in the MMP-9 gene are associated with 
susceptibility for onset of COPD in men. The increased risk 
for COPD may stem from the rare allele in exon 6, which 
replaces the non-charged glutamine (MMP-9Q) with the 
charged amino acid, arginine (MMP-9R). 
MMP-9R could increase degradation of the ECM 
leading to emphysematous lungs. MMP-9 is expressed and 
secreted from cells as inactive zymogen through multiple 
mechanisms. This inactive form of MMP-9 is maintained 
by a cysteine and additional domains within the highly 
conserved region of the pro-peptide and the essential zinc 
atom in the catalytic domain (Park et al 1991). This tight 
regulation may be diminished in MMP-9R, especially in 
the presence of inﬂ  ammatory responses that are induced by 
the presence of cigarette smoke. Alternatively, the afﬁ  nity 
of MMP-9R to tissue inhibitors of metalloproteinases 
(TIMP)-1, the major inhibitor of MMP-9, may be lower 
compared with that of MMP-9Q, because TIMP-1 forms a 
complex at the carboxy-terminus of the pro-enzyme and the 
catalytic domain of the active form (Goldberg et al 1992).
A previous study comparing smokers with COPD 
showed an association with a 5-year rate of decline with 
MMP-1 G-1607GG and haplotypes consisting of alleles 
from the MMP-1 G-1607GG and MMP-12 Asn357Ser 
polymorphisms (Joos et al 2002). In contrast, the CA repeat 
in MMP-9 was not associated with the rate of decline in 
Table 5 Association of genotypes with COPD
a
   All   Non-hispanic  white   Hispanic 
MMP-9  Gln279Arg   n   384   251   81 
   Heterozyg.    1.8 (1.1, 3.0) *    1.7 (0.9, 3.1)    2.9 (0.9, 9.5) 
   Homozyg.  rare    3.8 (1.8, 7.9) **    3.5 (1.5, 8.1) *    6.9 (0.4, 137.5) 
             
MMP-9  C/T-1562   n   372   242   78 
   Heterozyg.    1.3 (0.8, 2.3)    1.4 (0.7, 2.8)    1.7 (0.4, 7.7) 
   Homozyg.  rare    3.0 (0.8, 10.8)    4.5 (1.1, 10.4) *   NA
b 
              
MMP-9
c   CA repeat   n   366   236   79 
   Long/Short    1.1 (0.6, 1.9)    1.2 (0.6, 2.2)    2.4 (0.2, 26.1) 
   Long/Long      1.5 (0.8, 3.0)    2.3 (1.0, 5.1) *    2.4 (0.2, 29.0) 
             
MMP-1   n   379   246   81 
   Heterozyg.    1.2 (0.7, 2.2)    0.7 (0.3, 1.4)    2.09 (0.61, 7.15) 
   Homozyg.  rare    1.2 (0.7, 2.4)    0.9 (0.4, 2.0)   NA
b 
             
MMP-2   n   380   247   81 
   Heterozyg.    0.8 (0.5, 1.4)    0.8 (0.4, 1.5)    0.7 (0.2, 2.4) 
   Homozyg.  rare    0.7 (0.3, 1.8)    0.6 (0.2, 2.4)    2.3 (0.3, 17.4) 
aCOPD deﬁ  nition I.
bnot applicable due to zero participants with homozygous rare.
cOR (95% CI) relative to homozygous common and Short/Short CA repeats.
*p<0.05, ** p<0.001.
NOTE: Models include an adjustment for current smoking status and linear adjustments for age and smoking duration. 
Table 6 MMP-9 C/T-1562, Gln279Arg, and CA repeat 
haplotype frequencies
   Relative  frequency   Adjusted  OR
a
Haplotype
b    COPD
c   Non- Estimate   P  value 
   COPD     95% CI   
C-C-S   0.47   0.53   1.0    
C-C-L   0.11   0.19   0.8  (0.5–1.2)   0.26 
C-R-S   0.01   0.00       
C-R-L   0.23   0.15   1.8  (1.1–2.9)   0.02 
R-C-S   0.00   0.00       
R-C-L   0.00   0.00       
R-R-S   0.00   0.03       
R-R-L   0.18   0.13   1.7  (1.1–2.7)   0.03 
aLogistic model adjustments included age, smoking duration, and current smoking 
status.
bC-1562T (C=common, R=rare), Exon 6 (C=common, R=rare), CA repeat length 
(S=Short, L=Long).
cCOPD deﬁ  nition I.International Journal of COPD 2006:1(3) 275
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lung function. The differences in ﬁ  ndings from our study 
may be because the Joos et al study was designed to focus 
on the rate of decline in lung function rather than overall risk 
for developing COPD. That study also did not include the 
Gln279Arg SNP of MMP-9. As expected, the frequencies 
of the A (65%) and G (35%) alleles in our study were very 
similar to those reported previously (Zhang et al 1999a). In 
general the frequencies of the alleles for each of the SNPs 
in this study were very similar to those reported in the NCBI 
website or in manuscripts (Zhang et al 1999a; Hinoda et al 
2002).
The CA repeat length that was observed with high 
frequency in this cohort was 14 repeats. The second allele 
in these individuals had a CA repeat of 21, 22, or 23 repeats. 
The next most frequent alleles were between 21 and 22 
CA repeats. While a similar distribution in CA repeats 
was observed in a Caucasian population (Joos et al 2002), 
this distribution of CA repeats is vastly different from that 
reported for 223 Japanese who had primarily MMP-9 alleles 
that contained 20 or more CA repeats. Only 2.8% of the 
Japanese population studied had 1 or 2 alleles with fewer 
than 20 CA repeats (Shimajiri et al 1999). This difference 
in the distribution of CA repeat length may be signiﬁ  cant, 
because promoters with 21 CA repeats appeared to have a 
higher promoter activity compared with those with shorter 
repeats (Shimajiri et al 1999). In contrast, MMP-9 promoter 
containing 14 repeats had 53% promoter activity seen with 24 
CA repeats (Huang et al 2003). Similarly, Peters et al (1999) 
found that the promoter with 23 CA repeats showed a 1.5-fold 
higher promoter activity compared with those containing 21 
or 22 repeats. Consistent with these ﬁ  ndings, non-hispanic 
white participants in particular with the Long/Long genotype 
had an increased risk for COPD compared with those with a 
Short/Short genotype in our study.
The -1562T genotype was signiﬁ  cantly associated with 
increased risk for COPD in non-hispanic whites only. This 
ﬁ  nding supports the ﬁ  nding by Minematsu et al (2001) that 
the allelic frequency of the MMP-9 C-1562T promoter 
polymorphism was signiﬁ  cantly increased in 45 smokers 
with emphysema compared with 65 matched smokers 
without emphysema, when emphysematous changes were 
scored from chest computer tomography scans. However, 
they did not ﬁ  nd signiﬁ  cant differences when COPD was 
characterized by FEV1. Differences may be due to the 
association being speciﬁ  c for a speciﬁ  c ethnic group.
Non-hispanic whites were more likely to have COPD 
compared with hispanics and the decline in FEV1 was more 
pronounced in these participants compared with hispanics. 
In addition, all polymorphisms within MMP-9 that were 
tested were signiﬁ  cantly associated with COPD in the 
non-hispanic whites. The -1562T genotype was associated 
with COPD among the non-hispanic whites, but the 
genotype is rare and was not observed in the hispanics. 
The association for 279Arg and Long/Long form of CA 
repeat was similar for both ethnic groups, but the result 
was not statistically signiﬁ  cant for the hispanics, which 
may be a result of the smaller sample size. Collectively, 
these ﬁ  ndings suggest that, while the distribution of the 
genotypes may vary by ethnic group, the association between 
genotype and COPD is not affected by ethnicity. Thus, 
confounding by population admixture is unlikely to account 
for the observed associations. Whether this association is 
also found for women with COPD will be addressed in the 
future. 
Many studies have suggested the involvement of the 
MMPs in COPD (Ohnishi et al 1998; Vignola et al 1998; 
Segura-Valdez et al 2000;
 Imai et al 2001). Overexpression 
of MMP-1 results in emphysema in transgenic mice 
(D’Armiento et al 1992) and MMP-12 deﬁ  cient mice are less 
susceptible to cigarette smoke-induced emphysema compared 
with wild-type mice (Hautamaki et al 1997). However, the 
relevance of these animal models to human disease has not 
been proven. Our study supports the hypothesis that MMP-
9 may be a protease that is related to the pathogenesis of 
COPD and polymorphisms in MMP-9 may act as intrinsic 
factors to affect sensitivity to cigarette smoke-induced onset 
of COPD.
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Appendix
Table 4 Distribution of polymorphisms by COPD status (deﬁ  nition I) 
     All  participants    Participants with 2 visits 
     COPD   Non-COPD   COPD   Non-COPD 
MMP-9
a   Gln279Arg   C   35.0   52.1
**    35.4   52.3 
   H   46.3   40.2   37.5   41.4 
   R   18.7   7.7 
**    27.1   6.3 
   n   123   261   48   128 
                
MMP-9
a  C/T-1562   C   68.9   75.9   60.9   75.8 
   H   26.0   21.7   32.6   21.8 
   R   5.0   2.4   6.5   2.4 
   n   119   253   46   124 
                
MMP-9
b  CA repeat   SS   24.2   27.6   29.8   26.7 
   LS   46.7   50.0   34.0   52.5 
   LL   29.2   22.4   36.2   20.8 
   n   120   246   47   120 
                
MMP-1
a   C   26.2   27.2   22.9   25.0 
   H   46.7   46.3   47.9   46.9 
   R   27.1   26.5   29.2   28.1 
   n   122   257   48   128 
                
MMP-2
a   C   62.3   55.0   58.3   50.0 
   H   32.0   38.0   33.3   42.2 
   R   5.7   7.0   8.3   7.8 
   n   122   258   48   128 
aFor MMP-9 Gln279Arg, C-1562T, MMP-1, and MMP-2: C=common, H=heterozygote, R=rare.
bFor MMP-9 CA repeat length: S=Short, L=Long.
Difference between COPD (by deﬁ  nition I) and non-COPD participants: ** p<0.01, *p<0.05.
Table 5 Association of genotypes with COPD 
COPD deﬁ  nition II
      All   Non-hispanic  white   Hispanic 
Gln279Arg   n   366   238   76 
   Heterozyg.    2.04 (1.19, 3.49)*    1.75 (0.92, 3.35)    4.93 (1.26, 19.28) 
   Homozyg.  rare    3.13 (1.42, 6.94)**    2.77 (1.13, 6.81)*    12.61 (0.58, 275.15) 
             
C/T-1562   n   354   229   73 
   Heterozyg.    1.37 (0.77, 2.43)    1.48 (0.74, 2.96)    2.47 (0.55, 11.07) 
   Homozyg.  rare    2.24 (0.54, 9.30)    3.58 (0.72, 17.69)   NA
a 
             
CA repeat   n   348   223   74 
   Long-Short    1.35 (0.72, 2.52)    1.23 (0.62, 2.45)   NA
a 
   Long-Long    2.00 (0.97, 4.12)    1.98 (0.85, 4.63)   NA
a 
             
MMP1   n   361   233   76 
   Heterozyg.    1.28 (0.69, 2.36)    0.69 (0.32, 1.50)    3.19 (0.78, 12.30) 
   Homozyg.  rare    1.10 (0.54, 2.24)    0.85 (0.37, 1.93)   NA
a 
             
MMP2   n   362   234   76 
   Heterozyg.    0.85 (0.50, 1.43)    0.86 (0.46, 1.60)    0.61 (0.15, 2.41) 
   Homozyg.  rare    0.70 (0.25, 1.99)    0.78 ( 0.21, 2.90)    1.15 (0.10, 13.96) 
(Continued over)
anot applicable due to zero participants with homozygous rare. 
bOR (95% CI) relative to homozygous common and Short/Short CA repeats.
* p<0.05, ** p<0.001. 
NOTE: Models include an adjustment for current smoking status and linear adjustments for age and smoking duration. International Journal of COPD 2006:1(3) 278
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Table 5 (Continued)
COPD deﬁ  nition III
      All   Non-hispanic  white   Hispanic 
  Gln279Arg   n   339   217   74 
   Heterozyg.    1.78 (0.98, 3.23)    1.36 (0.65, 2.81)    4.08 (1.02, 16.27) 
   Homozyg.  rare    3.14 (1.35, 7.30)**    3.32 (1.31, 8.39)*    10.75 (0.50, 230.22) 
             
C/T-1562   n   327   208   71 
   Heterozyg.    1.31 (0.68, 2.53)    1.38 (0.63, 3.04)    2.22 (0.45, 10.89) 
   Homozyg.  rare    3.25 (0.78, 13.62)    5.08 (1.02, 25.18)*   NA
b 
             
CA repeat   n   321   202   72 
   Long-Short    1.29 (0.64, 2.61)    1.01 (0.46, 2.20)   NA
a 
   Long-Long    2.08 (0.94, 4.57)    2.16 (0.87, 5.36)   NA
a 
             
MMP1   n   334   212   74 
   Heterozyg.    1.31 (0.67, 2.54)    0.65 (0.29, 1.49)    3.17 (0.75, 13.41) 
   Homozyg.  rare    0.75 (0.33, 1.71)    0.55 (0.22, 1.39)   NA
a 
             
MMP2   n   335   213   74 
   Heterozyg.    0.83 (0.46, 1.51)    0.84 (0.42, 1.70)    0.77 (0.19, 3.12) 
   Homozyg.  rare    1.03 (0.36, 2.94)    1.16 (0.31, 4.39)    1.38 (0.11, 16.86) 
anot applicable due to zero participants with homozygous rare. 
bOR (95% CI) relative to homozygous common and Short/Short CA repeats.
* p<0.05, ** p<0.001. 
NOTE: Models include an adjustment for current smoking status and linear adjustments for age and smoking duration. 